Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Neogen Corporation. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Why Is Neogen Corporation (NEOG) Under Investigation?
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Neogen Corporation (“Neogen” or “the Company”) (NASDAQ: NEOG). Investors who purchased Neogen securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Neogen has violated federal securities laws.
What Potential Securities Violations Is BG&G Investigating?
On September 29, 2026, the U.S. Food and Drug Administration (“FDA”) announced that it had issued a warning letter to Neogen “following an investigation that linked a veterinary wound care product labeled as sterile, Neogen Vet HYCOAT (hyaluronate sodium sterile solution), to serious infections and deaths in horses.” The FDA said that “[t]his incident involved at least 20 horse deaths, making it the largest number of horse deaths ever associated with a quality defect in an FDA-regulated veterinary medical product and the most deaths of any animal species linked to microbiological contamination of an FDA-regulated product labeled as sterile” and further stated that “Neogen initiated a voluntary recall of HYCOAT in late January 2026.” Following this news, Neogen’s stock price fell $0.99 per share, or 7.22%, to close at $12.73 per share on September 29, 2026.
What Should Neogen Corporation (NEOG) Investors Do?
If you are aware of any facts relating to this investigation or purchased Neogen securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
How Did Neogen Corporation (NEOG) Stock React?
How Does BG&G Help Investors in Securities Fraud Investigations?
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”